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Summary
Background: Implantable cardioverter defibrillators
(ICD’s) are increasingly used for primary and
secondary prevention of sudden cardiac death.
However, data on how many ICD patients indeed
receive appropriate ICD therapy during long-term
follow-up is scarce.
Aim: The aim of our study was to determine the
number of patients without appropriate ICD therapy
5 years after ICD implantation, to identify predicting
factors, to assess the occurrence of late first ICD
therapy and to quantify the financial impact of
ICD therapy in a real-world setting.
Design: Prospective observational study.
Methods: We prospectively enrolled 322 con-
secutive ICD patients. Baseline data were collected
at implantation and patients were followed for a
median of 7.3 years (IQR 5.8–9.2 years). Time to
first appropriate ICD therapy (either antitachycardia
pacing or cardioversion) was documented.
Results: Five years after implantation, 139 patients
(43%) had not received appropriate ICD therapy. In
multivariable analysis, a primary prevention indica-
tion and negative electrophysiological studies prior
to ICD implantation were independent predictors of
freedom from ICD therapy. Of the patients without
ICD therapy, 5 years after implantation, 25% had
experienced inappropriate ICD shocks. Two hun-
dred and seven devices (1.5 devices per patient)
were needed for the 139 patients without ICD inter-
vention within 5 years, accounting for E31 784 per
patient. During an additional follow-up of 3 years,
12% of the patients with unused ICD received a late
first appropriate ICD therapy.
Conclusions: About half of the ICD patients receive
appropriate ICD therapy within 5 years after
implantation. Furthermore, there is a significant
proportion of patients receiving late first shocks
after five initially uneventful years.
Introduction
The benefits of implantable cardioverter defibrilla-
tors (ICD’s) in the primary and secondary prevention
of sudden cardiac death (SCD) have been estab-
lished in several studies.1–4 Based on these studies,
clinical indications for implantation of an ICD have
been expanded.5 In parallel, utilization of ICD has
steadily increased and is expected to do so over the
next years.6,7
Given the substantial costs of ICD therapy, serious
concerns have been raised regarding the effective-
ness and financial implications of this strategy.7,8
Of note, a substantial proportion of ICD patients
will never receive appropriate ICD therapy, reach-
ing 70–80% after 2 years in randomized controlled
trials.9 These patients nevertheless are at risk for
ICD complications such as inappropriate shocks,
infections and lead malfunction.10,11 Furthermore,
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device replacement is needed periodically due
to battery depletion roughly every 5 years.12–14
There is a feeling ‘once ICD, always ICD’,
indicating that usually the device is replaced with-
out repeated risk assessment at the time of battery
depletion.
Patients enrolled in randomized controlled trials
often differ significantly from real-world patients and
previous studies are limited because of their
short follow-up.15–17 The aim of our study was to
determine the number of patients without appropri-
ate ICD therapy at the time point of 5 years after
implantation, to identify predicting factors of an
unused ICD, to assess the occurrence of late first
ICD therapy and to quantify the financial impact




From March 1994 to October 2004, a total of 359
consecutive patients undergoing ICD implantation
for primary or secondary prevention were pro-
spectively enrolled to the ICD registry of the
Department of Cardiology, University Hospital
Basel, Switzerland. Time of last follow-up data
acquisition was end of November 2009. Thirty-
seven patients were excluded from current analysis
because of censored data earlier than 5 years of
follow-up without appropriate ICD therapy before.
The reasons for premature data censoring in these
patients were death [n=31; specific causes of
death were heart failure (n=11), SCD (n=1),
other cardiovascular death (n=6), noncardiac
death (n=9) and unknown cause of death
(n=4)], heart transplantation (n=2), device ex-
plantation (n=2) or refusal to replace the device
despite reaching end of life replacement indication
criteria (n=2). This left 322 patients with complete
follow-up information of a minimum of 5 years
(empirical time point of first-generator replace-
ment13,14) for analysis with a median follow-up
duration of 7.3 years [interquartile range (IQR)
5.8–9.2 years].
Indications for ICD implantation were based on
current guidelines.18–20 The secondary prevention
group consisted of patients with aborted SCD, sus-
tained or clinically critical ventricular tachycardia
(VT) or syncope with inducible VT. The implantation
policy of ICD primary prevention evolved over time,
similar to that for the patient populations enrolled in
recent trials.1–4 All devices used were endocardial,
transvenous ICDs implanted according to standard
practice.
Baseline examinations were carried out at the
time of ICD implantation and consisted of patient
demographics, comorbidities, New York Heart
Association (NYHA) classification, medication use,
type of underlying heart disease, index arrhythmia
or clinical event leading to device implantation and
results of electrophysiological studies (EPS). Left
ventricular ejection fraction (LVEF) was deter-
mined by echocardiography (biplane, Simpson’s
method).21
Follow-up assessment and event
ascertainment
Follow-up visits were performed 1 and 3 months
after ICD implantation and every 6 months there-
after. At each patient visit, a standard device inter-
rogation was performed by a cardiologist assisted by
a trained nurse.
A trained electrophysiologist (B.S.) classified all
stored intracardiac electrograms of ventricular
tachyarrhythmias responsible for ICD therapy,
together with the event date, and distinguished
appropriate from inappropriate ICD shocks.
Ambiguous cases were adjudicated in conjunction
with at least one further electrophysiologist (M.K.,
C.S. and S.O.). ICD shocks were considered
inappropriate when triggered by supraventricular
arrhythmias, sinus tachycardia, noise or T-wave
sensing. All visits were registered prospectively
and checked regularly for data consistency.
Appropriate ICD therapies were classified as fol-
lows: VT was terminated by antitachycardia pacing
or cardioversion with a detection rate determined at
the discretion of the managing cardiologist. In
primary prevention, detection rate was usually set
to 180 bpm. In secondary prevention, it was
programmed 20 beats slower than the documented
VT rate. Fast VT (FVT) was defined as a VT with
a heart rate >210 bpm and terminated by
shocks. Ventricular fibrillation (VF) was character-
ized by fibrillatory R waves and terminated by
defibrillation. Of note, this definition of appro-
priate ICD therapy involved an electrophysiologist’s
judgment of every event and hence does not
correspond to the clinical device setting, for which
the ‘VF zone’ is usually programmed at detection
rates >200–220/min. This modified definition was
used in order to be able to take ‘VF’ as a surrogate
marker for SCD.
We recorded date and reason for device
exchange if applicable. Patients with device
replacements were not removed from the analysis.
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Cost calculations
Assumptions for cost calculations were derived from
Belgian 2006 Health Care data as a model of a typ-
ical Western European country22,23. Initial implant-
ation was assumed to cause costs of E23 000,
generator replacement of E18 000, lead failure of
E6500 and lead infection of E28000.
Statistical methods
Continuous variables are presented as means (SD) or
medians (IQR) and categorical variables as numbers
and percentages. Continuous variables were com-
pared with the use of the Mann–Whitney U-test
and categorical variables with the use of the
Pearson’s chi-square test. We used univariate and
multivariate binary logistic regression models to
compute hazard ratios (HRs) and 95% confidence
intervals (95% CIs) of predictors of no ICD therapy
after 5 years. All hypothesis testing was two-tailed
and P<0.05 were considered to indicate statistical
significance. All statistical analyses were performed
with the use of SPSS for Windows 15.0 (SPSS Inc,
Chicago, IL, USA).
Results
Characteristics of the patients
Baseline characteristics of the 322 patients are
shown in Table 1. At ICD implantation, patients
were 60 (IQR 51–68) years old and predominantly
male (90%). The underlying heart disease was
coronary artery disease in 66% of patients, dilated
cardiomyopathy in 17% and other forms of cardio-
myopathy such as hypertrophic cardiomyopathy,
arrhythmogenic right ventricular cardiomyopathy
or valvular heart disease in the remaining patients
(17%). Indication for ICD therapy was secondary
prevention in 73% of patients.
Time course of first appropriate ICD
therapy within the first 5 years
Five year follow-up information was by study defin-
ition available in 100% of patients. Overall, 183
patients (57%) had received appropriate ICD
therapy at least once within 5 years whereas 139
patients (43%) were free of appropriate ICD therapy
5 years after implantation (Figure 1). This resulted in
a number needed to treat of 1.8 patients to achieve
an appropriate ICD therapy within 5 years. The
observed rates of appropriate ICD therapy varied
in important patient subgroups: there were more
appropriate ICD therapies within 5 years in patients
with a secondary prevention indication than in those
with a primary prevention indication (61 vs. 45%,
p=0.01), and more in patients with ischemic
cardiomyopathy compared to those with nonis-
chemic cardiomyopathy (61 vs. 49%, P=0.03). No
significant differences in appropriate ICD therapies
were observed between different ICD types (single
chamber 55%, dual chamber 61%, CRT 62%,
P=0.57).
Regarding the time course of events, the cumula-
tive percentage of patients with at least one appro-
priate ICD therapy increased from 26% of patients
after 6 months to 44% after 2 years and to 57% after
5 years (Figure 2). The rate of patients receiving first
appropriate ICD therapy in a given time period
dropped from 26% within the first 6 months down
to 2% between months 55 and 60.
Events in patients receiving appropriate
ICD therapy within 5 years
Patients receiving appropriate ICD therapy at least
once experienced a median of 10 episodes (IQR
2–30 episodes) of appropriate ICD therapy within
the first 5 years after implantation. Forty-eight
patients (15% of all patients) were treated for VF,
57 (18% of all patients) for FVT (but never for VF)
and 78 (24% of all patients) for VT (and thus never
for VF or FVT). In addition to receiving appropriate
ICD therapy, 31% of patients furthermore had
experienced inappropriate shocks as well. Five
years after implantation, 35 patients (19%) had
died having received appropriate ICD therapy
before at least once.
Predictors for no ICD therapy after 5 years
Patients without ICD therapy were younger, more
often had a primary prevention indication, had
higher baseline LVEF, were more often in NYHA
classes I and II, more often had negative EPS prior
to implantation and were less often on antiarrhyth-
mic drug therapy (Table 1). There were no differ-
ences for other medical therapies including
b-blockers, angiotensin converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs).
In multivariate binary logistic regression analysis,
primary prevention indication, NYHA class I/II and
freedom from antiarrhythmic drug use were inde-
pendent predictors of an unused ICD (Table 2,
Model 1). If results from EPS prior to implantation,
which were available in 228 patients were added,
only primary prevention indication (HR 1.98, 95%
CI 1.06–3.73, P=0.03) and negative EPS (HR 2.78,
95% CI 1.37–5.65, P=0.005) remained independ-
ent predictors of an unused ICD 5 years after
implantation (Table 2, Model 2).
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Inappropriate shocks in patients without
appropriate ICD-therapy
Of the patients without appropriate ICD therapy
after 5 years, 35 (25%) experienced at least one
episode of inappropriate ICD shocks. Among
these episodes, 14 (40%) were triggered by sinus
tachycardia, 10 (29%) by supraventricular arrhyth-
mias, 6 (17%) by noise and 5 (14%) by T-wave
sensing. No significant differences were observed
between different ICD types in terms of inappropri-
ate ICD shocks (single-chamber devices 25%,
dual-chamber devices 26%, CRT devices 27%,
P=0.98).
Device replacements and costs within the
first 5 years
Within 5 years after implantation, a total of 478
devices were needed for the 322 patients (1.5
devices per patient) with equal distribution between
patients receiving and not receiving appropriate ICD
therapy. Of the 156 device replacements, the reason
for change was end of life replacement indications
in 125 cases (80%), device recall in 15 cases (10%),
device upgrade in 5 cases (3%), lead dysfunction in
6 cases (4%) and infections in 5 cases (3%). Using
cost calculations based on Belgian Health Care
data,22,23 this resulted in ICD-related total costs of
Table 1 Baseline characteristics of the patients
All patients
Appropriate ICD therapy 5 years
after Implantation P-value
(n=322) No (n=139) Yes (n=183)
Age, median (quartiles) (years) 60 (51–68) 57 (45–64) 63 (56–70) <0.001
Gender: male, n (%) 289 (90) 120 (86) 169 (92) 0.08
Cardiomyopathy, n (%) 0.06
Coronary artery disease 213 (66) 83 (60) 130 (71)
Dilated cardiomyopathy 56 (17) 26 (19) 30 (16)
Other cardiomyopathy 53 (17) 30 (22) 23 (13)
Indication, n (%) 0.01
Primary prevention 86 (27) 47 (34) 39 (21)
Secondary prevention 236 (73) 92 (66) 144 (79)
LVEF, median (quartiles) (%) 35 (25–45) 35 (25–53) 32 (25–40) 0.006
NYHA Classification 0.01
NYHA Class I/II 250 (78) 117 (84) 133 (73)
NYHA Class III/IV 72 (22) 22 (16) 50 (27)
EPS (available in 228 points) 0.004
Positive 184/228 (81) 74/103 (72) 110/125 (88)
Negative 44/228 (19) 29/103 (28) 15/125 (12)
ICD type, n (%) 0.57
Single chamber (VVI) 224 (70) 101 (73) 123 (67)
Dual chamber (DDD or VDD) 69 (21) 27 (19) 42 (23)
Cardiac resynchronization therapy (CRT) 29 (9) 11 (8) 18 (10)
History, n (%)
Arterial hypertension 177 (55) 73 (53) 104 (57) 0.44
Diabetes mellitus 50 (16) 19 (14) 31 (17) 0.42
Previous myocardial infarction 211 (66) 83 (60) 128 (70) 0.06
Previous coronary artery bypass surgery 103 (32) 37 (27) 66 (36) 0.07
Previous percutaneous coronary intervention 114 (35) 51 (37) 63 (34) 0.07
Chronic renal failure 44 (14) 14 (10) 30 (16) 0.10
Medical therapy at implantation, n (%)
b-blocker 267 (83) 121 (87) 146 (80) 0.09
ACE inhibitor or ARB 267 (83) 111 (80) 156 (85) 0.20
Diuretic treatment 168 (53) 65 (57) 103 (56) 0.09
Amiodarone 90 (28) 27 (19) 63 (34) 0.003
Digoxin 33 (10) 10 (7) 23 (13) 0.11
Statins 174 (54) 121 (87) 146 (80) 0.09
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E10 195000 for the 322 patients, corresponding to
E31 568 per patient with appropriate ICD therapy
within 5 years and to E31784 per patient without
ICD intervention.
Time course and type of late first
appropriate ICD therapy beyond the
first 5 years
To analyze the likelihood of late first arrhythmia
occurrence, the 139 patients free of appropriate
ICD therapy after 5 years were followed for an
additional median of 1.3 years (IQR 1.0–4.0 years)
beyond the 5-year time point. The probability of
appropriate ICD therapy was 5% after 1, 9% after
2 and 12% after 3 additional years in these patients
(Figure 3). The additional 14 appropriate ICD thera-
pies were delivered for VF in 3, FVT in 4 and VT in
7 patients.
Table 2 Predictors for no ICD therapy 5 years after ICD implantation: binary logistic regression analysis
Variable Univariate Model Multivariate Model 1a Multivariate Model 2b
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age <60 years 2.10 (1.34–3.30) 0.001 n.s. n.s.
Cardiomyopathy other than CAD 1.66 (1.04–2.64) 0.03 n.s. n.s.
Primary prevention 1.89 (1.15–3.11) 0.01 1.79 (1.04–3.09) 0.04 1.98 (1.06–3.73) 0.03
LVEF >35% 1.57 (1.00–2.45) 0.05 n.s. n.s.
NYHA Class I/II 2.00 (1.14–3.50) 0.01 2.02 (1.11–3.70) 0.02 n.s.
Freedom of amiodarone therapy 2.18 (1.30–3.66) 0.003 1.83 (1.06–3.15) 0.03 n.s.
Negative results in EPS 2.87 (1.44–5.73) 0.003 2.78 (1.37–5.65) 0.005
aThe model was adjusted for age, type of cardiomyopathy, type of prevention, LVEF, NYHA class and amiodarone therapy.
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Figure 2. Time course of first appropriate ICD therapy over time. Proportion of patients free of ICD therapy so far with first
appropriate ICD therapy in a given time period since ICD Implantation (black). Cumulative proportion of patients in whom
at least one appropriate episode of ICD therapy has occurred since ICD implantation (white).
Figure 1. Timing of first appropriate ICD therapies.
Kaplan–Meier curve showing the timing of first appropri-
ate ICD therapies in all 322 patients.
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Discussion
This prospective observational study involving con-
secutive patients undergoing ICD implantation for
primary and secondary prevention with a median
follow-up of 7.3 years examined amount, predictors
and financial impact of patients without appropriate
ICD therapy at the time point of 5 years after
implantation. In contrast to other studies published
in the past, complete follow-up information is
available for at least 5 years in all patients.
We report four major findings: first, 57% of ICD
patients seen in daily practice received appropriate
ICD therapy within 5 years after implantation, while
43% of patients were free of appropriate ICD ther-
apy. The majority of ICD therapy was delivered for
potentially not life-threatening VTs. A primary
prevention indication and negative EPS prior to
ICD implantation were independent predictors of
freedom from appropriate ICD therapy after 5
years. Second, in patients free of appropriate ICD
therapy after 5 years, there is still a small, yet quan-
tifiable risk for late first arrhythmia occurrence
requiring appropriate ICD therapy reaching 12%
after three additional years. Third, 25% of the
patients without appropriate ICD therapy had experi-
enced at least one episode of inappropriate ICD
shock. Fourth, 1.5 devices per patient were needed
in patients without appropriate ICD therapy within
5 years accounting for cost of E31 784 per patient.
These findings derived from a large cohort of
consecutive ICD patients with detailed follow-up
and ICD therapy information for a minimum of
5 years in all patients are of great clinical import-
ance for three reasons: knowledge of and decisions
related to ICDs are based mainly on randomized
controlled trials.1–4 However, patients seen in the
community often differ substantially from patients
enrolled in randomized trials (Table 3). Second,
most studies examining predictors of occurrence of
VT and VF in ICD patients so far were limited by
a relatively short follow-up duration. And third,
since numbers of ICD implantations have steadily
increased in past years and are expected to increase
even more, medical and especially economic issues
associated with ICDs will become critical in the
future. A recent study by Cowie et al.23 using a
detailed meta-analysis of recent randomized con-
trolled ICD primary prevention trials demonstrated
that prophylactic ICD implantation in patients with
reduced LVEF is cost-effective in a European
health-care setting. Cost data on ICD therapy from
a European real-world setting, however, is rare.
The rate of 57% of patients receiving appropriate
ICD therapy equates to a number needed to treat of
1.8 patients to achieve an appropriate ICD therapy
within 5 years and reflects careful patient selection.
Furthermore, our study confirmed that there is still a
quantifiable, although small, risk for late appropriate
first ICD therapy even in patients without arrhythmic
events within the first 5 years after implantation.
However, it needs to be emphasized that 43% of
the appropriate ICD therapies that occurred in our
study were only for VT but never for VF or FVT.
It might be speculated that many of these VT
episodes would have terminated spontaneously or
might have been hemodynamically stable.24 If so,
ICD therapy cannot be considered life saving in
these patients,25 reducing the overall mortality
benefit provided by ICD therapy. Furthermore, the
proportion of ICD’s implanted for primary preven-
tion indications is rising continually with a lower
survival benefit demonstrated in these patients.2,4
Effective segregation of patients at high risk for
SCD from low risk patients is an unmet clinical
need. Earlier observational studies examining
mixed ICD populations have reported on unused
ICD rates of 82% after a mean follow-up of
13 months,17 82% after 18 months15 and 51%
after 30 months.16 In the only other large cohort
with a longer follow-up reported so far, Tandri
et al.26 found a proportion of 47% of patients with
unused ICD at a mean of 5.8 years after ICD
implantation. Selection of ICD patients as recom-
mended by current guidelines in primary
prevention is based almost exclusively on a
Figure 3. Late first appropriate ICD therapies in patients
free of appropriate ICD therapy 5 years after implantation.
Kaplan–Meier curve showing the incidence of late first
appropriate ICD therapies in the 139 patients that had
not received appropriate ICD therapy within the first
5 years after implantation.
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low EF.5 As shown by our study, other variables
such as a primary prevention indication and nega-
tive EPS testing prior to implantation significantly
and independently predicted use or nonuse of the
device, but the clinical value of these factors for
patient selection is limited due to rather small HRs.
Promising strategies to further improve the selection
of ICD patients include dynamic risk profiling using
repeated measures before implantation and risk
reassessment before device replacement on one
hand side as well as the use of additional risk
markers on the other hand side. The occurrence of
nonsustained VT, T-wave alternans, magnetic reson-
ance imaging, heart rate turbulence, QT variability
or genetic risk profiling are promising novel risk
markers currently under investigation.27–32 None of
these testing modalities has proven its value for
patient selection in prospective clinical trials yet,
but some may complement the ejection fraction
for the selection of ICD patients in the future.
Among the patients not receiving appropriate ICD
therapy within the first 5 years, 25% received
inappropriate shocks in our study. Inappropriate
shocks are known to result in multiple adverse
effects including psychiatric disturbances,33
impaired quality of life34 and provocation of subse-
quent ventricular arrhythmias.35 The use of longer
detection intervals has recently been shown to lower
the number of inappropriate ICD shocks and should
be helpful here.24
Potential limitations of the current study merit
consideration. First, even though this is a single-
center study, patient demographics are comparable
to several other studies including consecutive ICD
patients.16,26,36 Second, our population received
ICD implantation per definition from 1994 to
2004. ICD indications have expanded meanwhile5
and the majority of ICDs nowadays are implanted
for primary prevention indications. We therefore
assume that the proportion of patients with unused
ICDs will be higher in patients currently undergoing
ICD implantation. Third, we did not reassess the
patients at time of device replacement. Hence, it is
possible that the patients who received late first
appropriate ICD therapy >5 years after ICD implant-
ation developed new risk factors. Careful reassess-
ment of the arrhythmic risk profile should be carried
out at the time of replacement. And fourth, different
types of devices from different manufacturers
were used throughout the study period. Although
unlikely, we cannot exclude that this has to some
minor extent influenced our data.
Conclusion
About half of ICD patients seen in daily practice
receive appropriate ICD therapy within 5 years
after implantation, and there is a small, yet signifi-
cant proportion of patients receiving late first shocks
Table 3 Comparison of the study population to the populations in the primary and secondary prevention randomized
controlled ICD trials
BASEL 28 Prevention trials 18 Prevention trials
MADIT Ia AVIDb,c MADIT IId,e SCD-HeFTf
Patients in ICD group (n) 322 95 449 720 829
Age (years) 60 62 65 64 60
Gender: male (%) 90 92 79 84 77
Coronary artery disease (%) 66 100 81 100 52
Ejection fraction (%) 35 27 32 23 24
18 Prevention indication (%) 27 – – 100 100
28 Prevention indication (%) 73 100 100 – –
Appropriate ICD therapy in
18 prevention patients
45% in 5 years – – 35% in 3 years 21% in 5 years
Appropriate ICD therapy in
28 prevention patients
61% in 5 years 90% in 5 years 69% in 3 years – –
Appropriate ICD therapy overall 57% in 5 years – – – –
aMoss AJ. N Engl J Med 1996; 335:1933.
bThe AVID Investigators. N Engl J Med 1997; 337:1576.
cRaitt MH. Am J Cardiol 2003; 91:812.
dMoss AJ. N Engl J Med 2002; 346:877.
eMoss AJ. Circulation 2004; 110:3760.
fBardy GH. N Engl J Med 2005; 352:225.
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after five uneventful years. Knowledge of these num-
bers from a real-world cohort are important both for
careful patient selection before ICD implantation
and for reassessment of patients before generator
replacement.
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